@article{10c1866c12bc4f4887efb22625df47d6,
title = "Endophthalmitis after intravitreal injections",
abstract = "Endophthalmitis following intravitreal injection is an infrequent but serious clinical problem. Infectious endophthalmitis must be differentiated from noninfectious inflammation. Depending on the series, the risk of endophthalmitis is very low. The use of a standardized injection protocol can reduce the risk of infection.",
author = "Schwartz, {Stephen G.} and Flynn, {Harry W.} and Scott, {Ingrid U.}",
note = "Funding Information: This paper was partially supported by NIH center grant P30-EY014801 and by an unrestricted grant to the University of Miami from Research to Prevent Blindness, New York. SG Schwartz has received research funding from Genentech, owns equity in Pfizer and is co-holder of a patent pending entitled {\textquoteleft}Molecular targets for modulating intraocular pressure and differentiation of steroid responders versus nonresponders{\textquoteright}. The other two authors declare no conflicts of interest.",
year = "2009",
month = sep,
doi = "10.1517/14656560903081752",
language = "English (US)",
volume = "10",
pages = "2119--2126",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "13",
}